InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-33.2%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by MENDLEIN JOHN, Director. Director active across 1 company, notably Fate Therapeutics INC. Cumulatively, 7 disclosures have been recorded. Breakdown: 1 buy · 1 sell. Total volume traded: €494k. Activity tracked since 2 June 2021. The latest transaction was disclosed on 19 January 2023 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Declarations7 total
28,461 shares@ US$1.376.3% of flowCommon StockSEC:0001209191-23-004237:0
88,048 shares@ US$5.6780.7% of flowCommon StockSEC:0001209191-23-003338:0
Ideal exit: 8 Oct 2023 (T+270)
8,650 shares0Common StockSEC:0001209191-22-036350:0
1,364 shares@ US$22.790.014% mcap38.4% of flowCommon StockSEC:0001209191-22-034554:0
31,562 shares@ US$1.630.023% mcap61.6% of flowCommon StockSEC:0001209191-22-018188:0
2,681 shares0Common StockSEC:0000899243-21-022076:0
2,681 shares0Common StockSEC:0000899243-21-022076
7 of 7 declarations
About MENDLEIN JOHN
John Mendlein serves as a board member at FATE THERAPEUTICS INC. He contributes to the strategic direction of the company, ensuring that decisions made within the board align with growth objectives. His expertise in biotechnology is a valuable asset.
